---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-039399"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2026-02-05T23:59:59+00:00"
generated_at: "2026-05-16T04:28:23.070500+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences reports long-term TA-ERT data stabilizing cognition and motor skills in MPS IIIB

## Summary
- TA-ERT normalized CSF HS-NRE and stabilized Bayley-III cognitive scores over up to 6 years vs decline in natural history.
- VABS-II analysis showed stabilization of receptive/expressive communication and fine/gross motor skills.
- Sibling case study: treated child at 12.1 years spoke words and self-fed; untreated at 11.7 years was nonverbal and dependent.
- Safety consistent with ICV route; ~6,000 doses administered to 22 patients without new safety signals.
- Spruce plans to advance TA-ERT through BLA submission and potential FDA approval for MPS IIIB.

## SEC filing metadata
- accession: 0001193125-26-039399
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2026-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000119312526039399/0001193125-26-039399-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000119312526039399/sprb-20260205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-039399
- JSON: https://secwatch.observer/filing/0001193125-26-039399.json
- Plain text: https://secwatch.observer/filing/0001193125-26-039399.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.